A New Blueprint for Hope: How WideTrial Redefined Access to ALS Therapy

SAN JOSE, CA – June 29, 2026 – For patients with devastating diseases like Amyotrophic Lateral Sclerosis (ALS), the world of clinical trials can be a place of both immense hope and profound disappointment. Strict eligibility criteria, geographical distance, and the rapid progression of their illness often leave many on the outside looking in. Today, however, marks a significant milestone in bridging that gap. WideTrial Inc. announced that its landmark Expanded Access Program (EAP) for an investigational ALS therapy has reached its full enrollment of 200 patients, demonstrating a powerful new model for delivering treatment access and generating crucial scientific data simultaneously.

The program, known as SEANOBI-ALS, provided patients who were ineligible for traditional research studies with access to the investigational drug MN-166 (ibudilast). Its rapid success, enrolling 200 individuals across 27 states in less than 13 months, sends a clear signal to the industry: the need for scalable, well-managed compassionate use programs is immense, and a viable blueprint for executing them has now been established.

A Lifeline Outside the Trial System

For thousands of people living with ALS, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, time is the most precious commodity. Yet, the path to accessing promising new therapies is often a narrow one. Clinical trials, the gold standard for drug development, must adhere to rigid protocols with tight inclusion and exclusion criteria to ensure clean data. This necessary rigor means many patients—perhaps due to their age, the duration of their illness, or other health conditions—are unable to participate.

This is where Expanded Access Programs, also known as compassionate use, come in. Regulated by the FDA, EAPs offer a pathway for patients with serious or life-threatening conditions to gain access to investigational medical products outside of a formal trial. The SEANOBI-ALS program, managed by WideTrial, stands as a testament to the profound impact of this pathway. By building a network of 15 participating ALS clinics, the program effectively decentralized access, reaching patients far from major research hubs.

“The speed at which this program reached its capacity underscores the desperation and determination within the ALS community,” noted one healthcare policy analyst. “It’s a powerful indicator of the vast unmet need for treatment options beyond the confines of conventional trials.”

With enrollment now complete, the 200 patients currently in the program will continue to receive treatment and undergo follow-up activities according to the protocol. The final data collection is expected to conclude in early 2027, after which the findings will be analyzed for future scientific publications.

The Drug, the Data, and the Dual Mission

At the heart of the SEANOBI-ALS program is MN-166 (ibudilast), an investigational drug developed by MediciNova, Inc. The small molecule compound has a unique mechanism of action, believed to work by inhibiting neuroinflammation—a key process implicated in the progression of ALS. While it has been used in Japan for other conditions, its potential in ALS is still under formal investigation. MediciNova is currently running a separate, pivotal Phase 2b/3 clinical trial called COMBAT-ALS, with top-line results anticipated by the end of 2026.

The WideTrial program, however, was designed with a dual mission. Beyond providing access, its full name—Scalable Expanded Access with Analysis of Neurofilament and other Biomarkers in ALS—points to its secondary, but equally vital, objective. The program is systematically collecting real-world data, including levels of neurofilament light chain (NfL), a key biomarker that indicates nerve damage.

This approach is transformative. While the COMBAT-ALS trial will provide controlled efficacy data, the SEANOBI-ALS program will offer a wealth of real-world evidence from a more diverse patient population. This data can provide invaluable insights into how the drug performs in patients with different disease characteristics than those in the formal trial, potentially informing future research, treatment guidelines, and regulatory discussions. It moves EAPs from a simple act of compassion to a strategic component of the overall drug development lifecycle.

Architecting a Scalable Model for Compassionate Use

Historically, EAPs have often been ad-hoc, difficult to scale, and a logistical burden for drug developers who are primarily focused on securing regulatory approval. WideTrial, an emerging company with a mission to systematize this process, is changing that paradigm. The success of SEANOBI-ALS was not accidental; it was the result of a carefully architected model.

A critical catalyst for this model is the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS). Signed into law in 2021, this legislation authorized significant federal funding for EAPs. The SEANOBI-ALS program is a direct beneficiary, supported by a grant awarded to a large academic medical center partner through the National Institute of Neurological Disorders and Stroke (NINDS), a part of the NIH. This federal backing removes a significant financial barrier for drug sponsors and enables the creation of large-scale, structured programs.

By combining this public funding with its specialized management platform and a collaborative network of clinics, WideTrial has created a powerful public-private partnership. This structure proves that it is feasible to run large-scale compassionate use programs that are both efficient for clinics and beneficial for patients, setting a precedent that could be replicated for other serious diseases with limited treatment options.

Looking ahead, WideTrial has confirmed its commitment to building on this success. The company is already evaluating new opportunities in ALS and anticipates launching at least one additional large EAP in 2027, offering continued hope to patients and clinicians. The successful enrollment of SEANOBI-ALS is more than just a press release milestone; it represents a fundamental shift in how the industry can approach the ethical and scientific challenge of providing pre-approval drug access, turning a bottleneck into a bridge.